85 related articles for article (PubMed ID: 7170839)
1. The mouse as a model for evaluation of hypotriglyceridemic drugs effects of nicotinic acid, clofibrate and ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate on plasma lipoproteins.
Gustafsson K; Kiessling H
Z Versuchstierkd; 1982; 24(5-6):271-7. PubMed ID: 7170839
[No Abstract] [Full Text] [Related]
2. The spontaneously hyperlipidemic old rat as a model for evaluation of hypolipoproteinemic drugs. Effects of nicotinic acid, clofibrate and ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate on plasma lipoproteins.
Gustafsson K; Kiessling H
Z Versuchstierkd; 1982; 24(5-6):262-70. PubMed ID: 7170838
[No Abstract] [Full Text] [Related]
3. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
Schneider J; Mühlfellner G; Mühlfellner O; Hausmann L; Schubotz R
Arzneimittelforschung; 1980; 30(11b):2059-62. PubMed ID: 7194060
[TBL] [Abstract][Full Text] [Related]
4. Hypolipemic activity of clofibrate-related compounds.
Metz G; Specker M
Arzneimittelforschung; 1975 Nov; 25(11):1686-92. PubMed ID: 1243074
[TBL] [Abstract][Full Text] [Related]
5. Potential hypolipidemic agents. XVII. Synthesis and plasma lipid-lowering properties of compounds related to ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate and ethyl 2-(4-chlorophenoxy)-2-methylpropionate.
Högberg T; Bondesson G; Stjernström NE
Acta Pharm Suec; 1977; 14(2):149-60. PubMed ID: 906832
[No Abstract] [Full Text] [Related]
6. Evaluation of the hypolipaemic activity of etofylline clofibrate, a new ester of etofylline and clofibric acid, and comparison with effects of known hypolipaemic agents.
Davies JE; Kellett DN
Arzneimittelforschung; 1980; 30(11b):2035-7. PubMed ID: 7194055
[TBL] [Abstract][Full Text] [Related]
7. Hypolipaemic activity of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate) and its analogues in normolipaemic rats.
Ginocchio AV; Metz G
Arzneimittelforschung; 1980; 30(11b):2032-4. PubMed ID: 7194054
[TBL] [Abstract][Full Text] [Related]
8. Type III hyperlipoproteinaemia: the turnover rate of plasma triglycerides and the response to clofibrate.
Stuyt PM; Demacker PN; Stalenhoef AF; Schade RW; Lutterman JA; van't Laar A
Neth J Med; 1982; 25(8):245-54. PubMed ID: 7144991
[No Abstract] [Full Text] [Related]
9. [Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)].
Ditschuneit HH; Hutt V; Klör HU; Ditschuneit H
Arzneimittelforschung; 1980; 30(11b):2063-7. PubMed ID: 7194061
[TBL] [Abstract][Full Text] [Related]
10. Hypolipemic activity of plafibride.
Bruseghini L; Vilageliu J; Bagaria A
Arzneimittelforschung; 1981; 31(10a):1796-800. PubMed ID: 7198456
[TBL] [Abstract][Full Text] [Related]
11. Potential hypolipidemic agents. XIV. Synthesis and plasma lipid-lowering properties of substituted biphenyls, diphenyl ethers and benzofurans related to ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate.
Bondesson G; Högberg T; Misiorny A; Stjernström NE
Acta Pharm Suec; 1976; 13(2):97-106. PubMed ID: 937013
[No Abstract] [Full Text] [Related]
12. Hypolipemic activity of clofibrate-related compounds. 2nd Communication.
Metz G; Specker M
Arzneimittelforschung; 1977 Jul; 27(7):1421-4. PubMed ID: 578466
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and therapeutic evaluation of a new antilipemic substance].
de Aguiar Magano L
Arch Sci Med (Torino); 1980; 137(1):131-9. PubMed ID: 7458646
[TBL] [Abstract][Full Text] [Related]
14. [Arteriosclerosis--nicotinic acid therapy. 2. Alterations in serum lipoproteins. Diagnosis, therapy].
Gustafson A
Lakartidningen; 1971 Apr; 68(15):1744-5 passim. PubMed ID: 5577244
[No Abstract] [Full Text] [Related]
15. NAD+ biosynthesis from tryptophan in the presence of nicotinic acid or vice versa by rat hepatocytes--effect of clofibrate-feeding.
Shin M; Nakakita S; Hashimoto C; Sano K; Umezawa C
Int J Vitam Nutr Res; 1998; 68(2):104-8. PubMed ID: 9565825
[TBL] [Abstract][Full Text] [Related]
16. Combination of dietary phytosterols plus niacin or fenofibrate: effects on lipid profile and atherosclerosis in apo E-KO mice.
Yeganeh B; Moshtaghi-Kashanian GR; Declercq V; Moghadasian MH
J Nutr Biochem; 2005 Apr; 16(4):222-8. PubMed ID: 15808326
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and hypolipidemic evaluation of beta-alkylaminopropiophenone and beta-alkylaminopropio-2'-naphthone derivatives in rodents.
Huang Y; Hall IH
Pharmazie; 1996 Apr; 51(4):199-206. PubMed ID: 8628737
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and hypolipidaemic evaluation of a series of alpha-asarone analogues related to clofibrate in mice.
Labarrios F; Garduño L; Vidal MR; Garcia R; Salazar M; Martinez E; Diaz F; Chamorro G; Tamariz J
J Pharm Pharmacol; 1999 Jan; 51(1):1-7. PubMed ID: 10197410
[TBL] [Abstract][Full Text] [Related]
19. Potential hypolipidemic agents. 7. Synthesis and lipid-lowering properties of 2-(dibenzofuranyloxy)-2-methylpropionates and related compounds.
Bondesson G; Hedbom C; Högberg T; Magnusson O; Stjernström NE; Carlson LA
J Med Chem; 1974 Jan; 17(1):108-12. PubMed ID: 4808456
[No Abstract] [Full Text] [Related]
20. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
Oki JC
Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
